NO20065694L - Indolderivat med piperidinring - Google Patents

Indolderivat med piperidinring

Info

Publication number
NO20065694L
NO20065694L NO20065694A NO20065694A NO20065694L NO 20065694 L NO20065694 L NO 20065694L NO 20065694 A NO20065694 A NO 20065694A NO 20065694 A NO20065694 A NO 20065694A NO 20065694 L NO20065694 L NO 20065694L
Authority
NO
Norway
Prior art keywords
hydrogen atom
piperidine ring
receptor
indole derivative
group
Prior art date
Application number
NO20065694A
Other languages
English (en)
Inventor
Yuichi Suzuki
Koichi Ito
Atsushi Sasaki
Koshi Ueno
Miyuki Sakai
Hiroki Ishihara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20065694L publication Critical patent/NO20065694L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Foreliggende oppfinnelse angår en forbindelse representert ved følgende formel, et farmasøytisk akseptabelt salt derav, eller anvendelse derav som et farmasøytisk middel: hvori R1 og R2 er substituenter tilstøtende til hverandre og sammen med to karbonatomer til hver av hvilke de er bundet, danner en 5- til 7-leddet ikke-aromatisk karbocyklisk gruppe eller lignende, som kan være substituert med 1 til 4 substituenter valgt fra (1) en oksogruppe, (2) en hydroksylgruppe og lignende; R3 representerer et hydrogenatom eller lignende; og R6 representerer et hydrogenatom eller lignende. Denne forbindelsen har en overlegen styrke når det gjelder binding til en 5-HTlA reseptor og en antagonisme for reseptoren, og er anvendelig som et middel for behandling eller hindring av lavere urintraktsymptomer og særlig symptomer tilknyttet urinlagring.
NO20065694A 2004-05-12 2006-12-12 Indolderivat med piperidinring NO20065694L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004142437 2004-05-12
PCT/JP2005/008632 WO2005108389A1 (ja) 2004-05-12 2005-05-11 ピペリジン環を有するインドール誘導体

Publications (1)

Publication Number Publication Date
NO20065694L true NO20065694L (no) 2007-01-29

Family

ID=35310200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065694A NO20065694L (no) 2004-05-12 2006-12-12 Indolderivat med piperidinring

Country Status (18)

Country Link
US (2) US20050256103A1 (no)
EP (1) EP1757599A4 (no)
JP (1) JP3902221B2 (no)
KR (1) KR100788862B1 (no)
CN (1) CN1984900B (no)
AU (1) AU2005240928B2 (no)
BR (1) BRPI0510971A (no)
CA (1) CA2564062C (no)
IL (1) IL178940A (no)
MX (1) MXPA06013034A (no)
MY (1) MY138420A (no)
NO (1) NO20065694L (no)
NZ (1) NZ551024A (no)
RU (1) RU2332413C1 (no)
SA (1) SA05260119B1 (no)
TW (1) TWI391387B (no)
WO (1) WO2005108389A1 (no)
ZA (1) ZA200609225B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI391387B (zh) 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
US20080119518A1 (en) * 2005-02-04 2008-05-22 Yuichi Suzuki 1-(Piperidin-4- Yl)-1H-Indole Derivatives
US20080227815A1 (en) * 2005-05-11 2008-09-18 Takahisa Sakaguchi Crystal of Indole Derivative Having Piperidine Ring and Process for Production Thereof
JP4932717B2 (ja) * 2005-05-11 2012-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピペリジン環を有するインドール誘導体の製造方法
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
US8143285B2 (en) * 2005-09-06 2012-03-27 Shionogi & Co., Ltd. Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity
JP2009511530A (ja) * 2005-10-13 2009-03-19 モルフォケム アクチェンゲゼルシャフト フュア コンビナトリシェ ヘミー 抗菌活性を有する５−キノリン誘導体
US7541371B2 (en) * 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease
JP2008169191A (ja) * 2006-02-20 2008-07-24 Eisai R & D Management Co Ltd 運動ニューロン疾患治療剤
JP2009544609A (ja) * 2006-07-18 2009-12-17 アストラゼネカ・アクチエボラーグ 置換２−アセチルアミノ−アルコキシフェニルの製造方法
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
US20080199518A1 (en) * 2006-11-28 2008-08-21 Wyeth Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution
US20080226714A1 (en) * 2007-02-16 2008-09-18 Wyeth Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
TWI410420B (zh) 2008-02-05 2013-10-01 Dainippon Sumitomo Pharma Co 苄基哌啶化合物
EP2313379B1 (en) * 2008-05-30 2015-03-11 Emcure Pharmaceuticals Limited Process for the preparation of efavirenz
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
WO2011016468A1 (ja) 2009-08-04 2011-02-10 大日本住友製薬株式会社 ベンジルピペリジン化合物
EP2672847B1 (de) 2011-02-11 2015-04-22 Batmark Limited Inhalatorkomponente
CA2854266A1 (en) 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2014102588A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
GB2535427A (en) 2014-11-07 2016-08-24 Nicoventures Holdings Ltd Solution
GB2542838B (en) 2015-10-01 2022-01-12 Nicoventures Trading Ltd Aerosol provision system
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20220378756A1 (en) 2019-09-19 2022-12-01 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113717091B (zh) * 2021-09-28 2023-03-10 南京医科大学 一类吲哚衍生物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US20020193383A1 (en) * 1997-08-01 2002-12-19 Recordati S.A., Chemical And Pharmaceutical Comoany 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring
IT1293807B1 (it) * 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
GB9825413D0 (en) 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10000739A1 (de) * 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
US6844338B2 (en) * 2000-05-18 2005-01-18 Eli Lilly And Company Piperidyindoles as serotonin receptor ligands
GB2362381A (en) 2000-05-18 2001-11-21 Lilly Co Eli Pharmaceutically active indolyl-piperidines
UA73995C2 (en) * 2000-07-21 2005-10-17 Lundbeck & Co As H Indole derivatives being useful for the treatment of cns disorders,, a pharmaceutical composition and a method for treatment
JP2002114684A (ja) * 2000-10-03 2002-04-16 Eisai Co Ltd 尿路疾患治療剤
WO2003059351A1 (en) * 2001-12-21 2003-07-24 Eisai Co., Ltd. Hydroxylated indole derivatives and uses thereof
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
TWI391387B (zh) 2004-05-12 2013-04-01 Eisai R&D Man Co Ltd 具有哌啶環之吲哚衍生物
US20080119518A1 (en) 2005-02-04 2008-05-22 Yuichi Suzuki 1-(Piperidin-4- Yl)-1H-Indole Derivatives
EP1880995B1 (en) 2005-05-11 2011-12-21 Eisai R&D Management Co., Ltd. Method for producing indole derivative having piperidine ring
KR20080007649A (ko) 2005-05-11 2008-01-22 에자이 알앤드디 매니지먼트 가부시키가이샤 피페리딘환을 가지는 인돌 유도체의 결정 및 그의 제조방법
US7541371B2 (en) * 2006-02-20 2009-06-02 Eisai R&D Management Co., Ltd. Method for treating a motor neuron disease

Also Published As

Publication number Publication date
US20070219179A1 (en) 2007-09-20
IL178940A (en) 2011-02-28
CA2564062A1 (en) 2005-11-17
JP3902221B2 (ja) 2007-04-04
MY138420A (en) 2009-06-30
BRPI0510971A (pt) 2007-12-04
CN1984900A (zh) 2007-06-20
AU2005240928A1 (en) 2005-11-17
AU2005240928B2 (en) 2010-08-19
RU2006143769A (ru) 2008-06-20
EP1757599A1 (en) 2007-02-28
US7538123B2 (en) 2009-05-26
EP1757599A4 (en) 2010-07-14
SA05260119B1 (ar) 2008-11-17
RU2332413C1 (ru) 2008-08-27
HK1100410A1 (en) 2007-09-21
KR20070011553A (ko) 2007-01-24
IL178940A0 (en) 2007-03-08
MXPA06013034A (es) 2006-12-20
NZ551024A (en) 2009-06-26
TWI391387B (zh) 2013-04-01
WO2005108389A1 (ja) 2005-11-17
ZA200609225B (en) 2008-07-30
CN1984900B (zh) 2010-11-10
JPWO2005108389A1 (ja) 2008-03-21
KR100788862B1 (ko) 2007-12-27
TW200540174A (en) 2005-12-16
CA2564062C (en) 2012-07-10
US20050256103A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
NO20065694L (no) Indolderivat med piperidinring
AU2022203948B2 (en) Apoptosis-Inducing Agents
RU2386623C2 (ru) Новые модуляторы дофаминовой нейротрансмиссии
Feng et al. Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives
AU2016215033B2 (en) (9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
NO20054952L (no) 2,3,6-trisubstituerte 4-pyrimidonderivater
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
NO20072115L (no) Farmasoytiske forbindelser
JP3176935B2 (ja) ドーパミンリセプタサプタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
UA73337C2 (en) Dopamine neurotransmission modulators
NO170081B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolderivater med aktivitet paa kolinerge system
WO2007143523A3 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
TNSN08499A1 (en) CRYSTALLINE FORMS OF 11 ß-(4-ACETYLPHENYL)-20,20,21,21,21-PENTAFLUOR-17- HYDROXY-19-NOR-17α-PREGNA-4,9-DIEN-3-ONE
EP3174860A1 (en) Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
NO20073271L (no) Nye pyridotienopyrimidinderivater
Xu et al. Ciprofloxacin–Isatin hybrids and their antimycobacterial activities
Zhang et al. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs
ES2374629T3 (es) Nuevos derivados de bencil(iden)-lactama.
NO20051901L (no) Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
NO20080262L (no) Fremgangsmate for produksjonen av intermediater for fremstilling av tricykliske benzimidazoler
NO20071209L (no) Pyrrolderivater, deres fremstilling og deres terapeutiske anvendelse
ATE396183T1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
NO20081789L (no) Substituert sykloalkenderivat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application